Ankylosing Spondylitis
IL-6, JAK inhibitors, rituximab increase severe infection risk in inflammatory arthritis
WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.
Median survival of first-line TNF inhibitor in ankylosing spondylitis nearly 11 years
Patients with ankylosing spondylitis starting their first TNF inhibitor, and who stayed on said treatment for at least 2 years, demonstrated a median drug survival period of 10.6 years, with 24% discontinuing, according to data.
FDA OKs Bimzelx for psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA
The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according to a press release.
Higher secukinumab dose yields no clinical difference after inadequate response in AS
Increasing the dosage of secukinumab failed to improve ankylosing spondylitis outcomes among patients who initially demonstrated an inadequate treatment response, according to data published in Rheumatology.
Diagnosis and Evaluation of PsA
TNF-Blocking Therapies
TNF inhibitors equally safe, effective in young- and late-onset ankylosing spondylitis
TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of whether the disease developed early or late in life, according to data published in Scientific Reports.